'Super-Enrichment' reveals dose-dependent therapeutic effects of environmental stimulation in a transgenic mouse model of Huntington's disease

Journal of Huntington's Disease

Volumn 3, Issue 3, 2014, Pages 299-309

  Mazarakis, Nektarios K ^a,c   Mo, Christina ^b   Renoir, Thibault ^b   Van Dellen, Anton ^a   Deacon, Robert ^a   Blakemore, Colin ^a   Hannan, Anthony J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Cerebral cortex; cognitive stimulation; dopamine; environmental enrichment; experience dependent plasticity; neurodegeneration; physical activity; polyglutamine; striatum; tandem repeat disorder

Indexed keywords

DOPAMINE RECEPTOR; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN SIZE; BRAIN WEIGHT; CONTROLLED STUDY; ENVIRONMENTAL ENRICHMENT; ENVIRONMENTAL STIMULATION; GRIP STRENGTH; HUNTINGTON CHOREA; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ROTAROD TEST; SENSORIMOTOR CORTEX; STIMULATION; THERAPY EFFECT; ANIMAL; ANIMAL BEHAVIOR; ENVIRONMENT; FEMALE; HUNTINGTON DISEASE; MOTOR ACTIVITY; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; ENVIRONMENT; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONAL PLASTICITY; TREATMENT OUTCOME;

EID: 84925257158     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140118     Document Type: Article

References (38)

1. Huntington's Disease Collaborative Research, Group.Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-83.
2. Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Annals Neurol. 2002;51(2):235-42.
3. Nithianantharajah J, Barkus C, MurphyM, Hannan AJ. Geneenvironment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis. 2008;29(3): 490-504.
4. Pang TYC,DuX, Zajac MS,Howard ML, Hannan AJ. Altered serotonin receptor expression is associated with depressionrelated behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet. 2009;18(4):753-66.
5. Renoir T, Pang TYC, Mo C, Chan G, Chevarin C, Lanfumey L, Hannan AJ. Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice. J Physiol. 2013;591(1):41-55.
6. Spires TL, Grote HE, Varshney NK, Cordery PM, van Dellen A, Blakemore C, Hannan AJ. Environmental enrichment, rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci. 2004;24(9):2270-6.
7. van Dellen A, Blakemore C, Deacon R, York D, Hannan AJ. Delaying the onset of Huntington's in mice. Nature. 2000;404(6779):721-2.
8. Rabipour S, Raz A. Training the brain: Fact and fad in cognitive and behavioral remediation. Brain Cognition. 2012;79(2):159-79.
9. Sale A, Berardi N, Maffei L. Enrich the environment to empower the brain. Trends Neurosci. 2009;32(4):233-9.
10. Hutchinson E, Avery A, VandeWoude S. Environmental enrichment for laboratory rodents. ILAR J. 2005;46(2):148-61.
11. Olsson IAS, Dahlborn K. Improving housing conditions for laboratory mice: A review of 'environmental enrichment'. Lab Animals. 2002;36(3):243-70.
12. Wood NI, Carta V, Milde S, Skillings EA, McAllister CJ, Ang YLM, et al. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS ONE. 2010;5(2):e9077.
13. Wood NI, Glynn D, Morton AJ. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2011;42(3): 427-37.
14. Lione LA, Carter RJ, Hunt MJ, Bates GP,Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci. 1999;19(23):10428-37.
15. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon I. of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506.
16. Paxinos G, Franklin K. The Mouse Brain in Sterotaxis Coordinates. 2nd edn. San Diego, CA, USA: Academic Press; 2001.
17. Hickey MA, Reynolds GP, Morton AJ. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. J Neurochem. 2002;81(1):46-59.
18. Cha J-HJ, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, DaviesSW, Penney JB, Bates GP,Young AB. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc Natl Acad Sci U S A. 1998;95(11):6480-5.
19. Lawrence AD,Weeks RA, Brooks DJ, Andrews TC,Watkins LH, Harding AE, Robbins TW, Sahakian BJ. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain. 1998;121(Pt 7):1343-55.
20. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Annals Neurol. 1996;40(1):49-54.
21. Robertson GS, Vincent SR, Fibiger HC. Striatonigral projection neurons contain D1 dopamine receptor-Activated c-fos. Brain Res. 1990;523(2):288-90.
22. Robertson GS, Vincent SR, Fibiger HC. D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience. 1992;49(2):285-96.
23. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537-48.
24. Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington's disease mice. Neurobiol Dis. 2014;69:248-62.
25. Barreto G, Huang TT, Giffard RG. Age-related defects in sensorimotor activity spatial learning and memory in C57BL/6 mice. J Neurosurg Anesthesiol. 2010;22(3):214-9.
26. Kosinski CM, Schlangen C, Gellerich FN, Gizatullina Z, Deschauer M, Schiefer J, et al. Myopathy as a first symptom of Huntington's disease in a Marathon runner. Mov Disord. 2007;22(11):1637-40.
27. Pang TYC, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience. 2006;141(2):569-84.
28. DuanW, Guo Z, Jiang H,Ware M, Li X, Mattson M. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A. 2003;100(2911-2916).
29. Du X, Leang L, Mustafa T, Renoir T, Pang TY, Hannan AJ. Environmental enrichment rescues female-specific hyperactivity of the hypothalamic-pituitary-Adrenal axis in a model of Huntington's disease. Transl Psychiatry. 2012;2:e133.
30. Spektor BS, Miller DW, Hollingsworth ZR, Kaneko YA, Solano SM, Johnson JM, Penney JB, Young AB, Luthi-Carter R. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease. Mol Brain Res. 2002;102(1-2): 118-28.
31. Renoir T, Argyropoulos A, Hannan AJ. Antidepressant-like effect of the norepinephrine-dopamine reuptake inhibitor bupropion in a mouse model of Huntington's disease with dopaminergic dysfunction. J Huntington's Dis. 2012;1(2):261-6.
32. Michalik A, Van Broeckhoven C. Pathogenesis of polyglutamine disorders: Aggregation revisited. Hum Mol Genet. 2003;12(suppl 2):R173-R86.
33. BennCLP, Luthi-CarterRP,KuhnAP, Sadri-VakiliGP, Blankson KL, Dalai SCM, et al. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol. 2010;69(8):817-27.
34. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805-10.
35. Trembath K, Horton Z, Tippett L, Hogg V, Collins V, Churchyard A, Velakoulis D, Roxburgh R, Delatycki MB. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord. 2010;58:179-82.
36. Sullivan FR, Bird ED, Alpay M, Cha JH. Remotivation therapy and Huntington's disease. The Journal of Neuroscience Nursing: Journal of the American Association of Neuroscience Nurses. 2001;33(3):136-42.
37. Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A, Zappata P, Frontali M, Jacopini G. Effects of an intensive rehabilitation programme on patients with Huntington's disease: A pilot study. Clin Rehabil. 2007;21(7):603-13.
38. McOmish CE, Hannan AJ. Enviromimetics: Exploring gene environment interactions to identify therapeutic targets for brain disorders. Expert Opin Ther Targets. 2007;11(7):899-913.